Table 2. Overall survival in 3 years and 5 years and disease-free survival of included studies.
| Study or Subgroup | Intervention | OS (HR and 95% CI) | DFS (HR and 95%CI) | |||
|---|---|---|---|---|---|---|
| Treatment (Size) | 3-year | 5-year | ||||
| Law et al., 1997 | CT+S | /S | (74/73) | - | 0.73 (0.53, 1.00) | - |
| Ancona et al., 2001 | CT+S | /S | (47/47) | - | 0.84 (0.58, 1.10) | - |
| Kelsen et al., 2007 | CT+S | /S | (216/227) | 1.05 (0.88, 1.26) | 1.06 (0.89, 1.25) | - |
| Allum et al., 2009 | CT+S | /S | (400/402) | 0.84 (0.70, 1.01) | 0.84 (0.58, 1.10) | 0.82 (0.71, 0.95) |
| Boonstra et al., 2011 | CT+S | /S | (85/84) | 0.65 (0.53, 0.80) | 0.66 (0.55, 0.80) | 0.72 (0.52, 1.00) |
| Ando et al., 2012 | CT+S | /S | (164/166) | 0.71 (0.53, 0.95) | 0.67 (0.52, 0.87) | 0.73 (0.54, 0.99)*** |
| Maipang et al., 1994 | CT+S | /S | (24/22) | 1.08 (0.79, 1.48) | - | - |
| Nygaard et al., 1992 * | CT+S | /S | (50/41) | 1.10 (0.93, 1.30) | - | - |
| Nygaard et al., 1992 * | CRT+S | /S | (47/41) | 0.8 (0.63, 1.02) | - | - |
| Nygaard et al., 1992 * | RT+S | /S | (48/41) | 0.76 (0.45, 1.28) | - | - |
| Schlag et al., 1992 | CT+S | /S | (22/24) | 0.97 (0.60, 1.57) | 0.97 (0.60, 1.57) | - |
| Ychou et al., 2011 | CT+S | /S | (113/111) | 0.69 (0.50, 0.95) | - | 0.69 (0.50, 0.95) |
| Pouliquen et al., 1996 | CT+S | /S | (52/68) | 0.99 (0.84, 1.17) | 1.00 (0.86, 1.18) | - |
| Ando et al., 1997 | CT+S | /S | (105/100) | 0.87 (0.65, 1.18) | 1.00 (0.86, 1.18) | - |
| Ando et al., 2003 | CT+S | /S | (120/122) | 0.77 (0.56, 1.07) | 0.75 (0.56, 0.99) | 0.73 (0.54, 0.99) |
| Lee et al., 2005 | CT+S | /S | (40/52) | 0.85 (0.66, 1.08) | 0.86 (0.68, 1.09) | 0.68 (0.55, 0.83) |
| Heroor et al., 2003 | CT+S | /S | (94/117) | 1.24 (0.94, 1.65) | 1.31 (1.03, 1.67) | - |
| Shiozaki et al., 2004 | CT+S | /S | (98/52) | - | 0.48 (0.35, 0.66) | - |
| Zhang et al., 2008 | CT+S | /S | (66/160) | 1.36 (0.93, 1.98) | - | 1.80 (1.26, 2.59) |
| Walsh et al., 1996 | CRT+S | /S | (55/55) | - | 0.53 (0.33, 0.84) | - |
| Urba et al., 2001 | CRT+S | /S | (47/50) | 0.75 (0.46, 1.22) | - | - |
| Stahl et al., 2009 | CRT+S | /CT+S | (60/59) | - | 0.67 (0.41, 1.09) | - |
| Burmeister et al., 2011 | CRT+S | /CT+S | (39/36) | 0.59 (0.46, 0.77) | 0.63 (0.49, 0.81) | 0.74 (0.53, 1.02)*** |
| Tepper et al., 2008 | CRT+S | /S | (30/26) | 0.55 (0.40, 0.76) | 0.52 (0.39, 0.70) | 0.35 (0.27, 0.46)*** |
| van Hagen et al., 2012 | CRT+S | /S | (178/188) | - | 0.73 (0.53, 1.00) | - |
| Burmeister et al., 2005 | CRT+S | /S | (128/128) | 0.87 (0.72, 1.05) | 0.88 (0.73, 1.06) | 0.82 (0.71, 0.95)*** |
| Lv et al., 2010 ** | CRT+S | /S | (80/80) | 0.85 (0.61, 1.18) | 0.83 (0.63, 1.08) | 0.66 (0.55, 0.78)*** |
| Lv et al., 2010 ** | CRT+S | /S | (78/80) | 0.73 (0.55, 0.98) | 0.76 (0.60, 0.97) | 0.70 (0.59, 0.83)*** |
| Apinop et al., 1994 | CRT+S | /S | (35/34) | 0.80 (0.48, 1.34) | 0.80 (0.48, 1.34) | - |
| Le Prise et al., 1994 | CRT+S | /S | (41/45) | 0.85 (0.50, 1.46) | 0.85 (0.50, 1.46) | 0.75 (0.64, 0.90) |
| Walsh et al., 1995 | CRT+S | /S | (58/55) | 0.58 (0.38, 0.88) | 0.58 (0.38, 0.88) | - |
| Mariette et al., 2014 | CRT+S | /S | (98/97) | 0.99 (0.69, 1.40) | - | - |
| Kobayashi et al., 2000 | CT+S | /S | (91/80) | 1.10 (0.67, 1.81) | 1.10 (0.67, 1.81) | - |
| Launois et al., 1981 | RT+S | /S | (67/57) | 1.17 (1.04, 1.32) | 1.17 (1.04, 1.32) | - |
| Gignoux et al., 1987 | RT+S | /S | (115/114) | 1.07 (0.89, 1.29) | 1.04 (0.87, 1.24) | - |
| Arnott et al., 1992 | RT+S | /S | (90/86) | - | 1.02 (0.87, 1.19) | - |
| Lee et al., 2004 | CRT+S | /S | (51/50) | 1.19 (0.92, 1.56) | - | 0.98 (0.55, 1.72) |
Abbreviation: OS-Overall survival, DFS-Disease-free survival, HR-Hazard ratio, CI-Confidence interval, CRT-chemoradiotherapy, S-surgery, CT-chemotherapy, RT-radiotherapy
Note: *: These three studies are from the same paper. **: These two studies are from the same paper. The first one is the preoperative group and the latter one is the postoperative group. ***: Progression-Free Survival